A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab
NCT ID: NCT04112498
Last Updated: 2023-04-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
24 participants
INTERVENTIONAL
2019-10-01
2023-02-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma
NCT03484819
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
NCT03607890
Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)
NCT02181738
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
NCT04080804
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
NCT05010005
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
nivolumab + relatlimab + rHuPH20
relatlimab
Specified dose on Specified days
nivolumab
Specified dose on Specified days
rHuPH20
Specified dose on Specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
relatlimab
Specified dose on Specified days
nivolumab
Specified dose on Specified days
rHuPH20
Specified dose on Specified days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Melanoma
* Metastatic squamous or non- squamous non-small cell lung cancer (NSCLC)
* Gastric adenocarcinoma (includes gastro-esophageal junction)
* Hepatocellular carcinoma (HCC)
* Squamous cell carcinoma of the head and neck (SCCHN)
* Renal cell carcinoma (RCC)
* Bladder cancer
* Participants must have received available standard therapies
* Women and men must agree to follow instructions for method of contraception
* Measureable disease as per RECIST version 1.1 criteria
* Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Exclusion Criteria
* Participants with HCC must not have any history of hepatic encephalopathy, any prior (within 1 year) or current clinically significant ascites
* History of allergy or hypersensitivity to study drug components
* Participants with serious or uncontrolled cardiovascular disease
* Excluding patients with serious or uncontrolled medical disorders
* Participants with a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of start of study treatment
* Participants with an active, known, or suspected autoimmune disease
* Participants must not have evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 0001
Hackensack, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CA224-087
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.